Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020


 

Management of MF in 2020: Rux Failure, Fedratinib Approval, Data on Navitoclax, Luspatercept, Pacritinib, and Momelotinib

57 views
March 4, 2020
0 Comments
Login to view comments. Click here to Login
Malignant Hematology